Fasting Insulin
Detecting insulin resistance 10–15 years before blood glucose becomes abnormal
A high fasting insulin with normal glucose is the signature of compensated insulin resistance — when the pancreas is working harder than it should just to keep blood sugar in range. This is the earliest metabolic warning sign, and the widest window for effective intervention.
Insulin is the pancreatic hormone enabling cellular glucose uptake. In insulin resistance — the foundation of type 2 diabetes, PCOS, and metabolic syndrome — cells stop responding normally, forcing the pancreas to produce more insulin for the same effect. For years, fasting glucose remains normal because the pancreas compensates (hyperinsulinaemia). A high fasting insulin with normal glucose is the clinical signature of this compensated phase — the optimal intervention window.
Reference Ranges
How clinicians interpret Fasting Insulin results — from optimal to concerning.
⚠ Reference ranges vary by laboratory and assay. Always interpret your result in context of your laboratory's own reference intervals and your clinical presentation.
What raises Fasting Insulin
Central obesity, hypertension, dyslipidaemia drive insulin resistance — the pancreas compensates with hyperinsulinaemia.
Insulin resistance in 50–70% of PCOS — hyperinsulinaemia drives ovarian androgen overproduction.
Insulin-secreting pancreatic tumour — causes both hyperinsulinaemia and fasting hypoglycaemia.
Cortisol excess promotes hepatic gluconeogenesis and adipose insulin resistance.
Before beta-cell exhaustion — compensatory hyperinsulinaemia as the pancreas fights rising glucose.
What lowers Fasting Insulin
Even 5–10% body weight loss significantly reduces fasting insulin by reducing adipose-driven inflammation and improving insulin sensitivity.
GLUT4 upregulation in muscle tissue reduces insulin requirement for glucose uptake — insulin levels fall with regular exercise.
Reducing carbohydrate intake reduces postprandial insulin demand — fasting insulin falls within weeks of dietary change.
Improves hepatic insulin sensitivity and reduces gluconeogenesis — lowers fasting insulin by 10–20%.
Improve insulin sensitivity and reduce hepatic glucose output — semaglutide reduces fasting insulin significantly alongside weight loss.
Conditions this biomarker signals
When Fasting Insulin is outside normal range, these are the most clinically significant possibilities.
Fasting insulin > 10 with normal glucose = the early IR window. Lifestyle intervention now prevents T2DM, NAFLD, PCOS, CVD progression.
50–70% have elevated fasting insulin — drives androgen excess and menstrual irregularity. Metformin targets this mechanism.
Fasting insulin > 6 µIU/mL with glucose < 3.0 mmol/L during supervised fast = Whipple's triad. Urgent pancreatic imaging.
Very low fasting insulin with elevated glucose = insufficient production. Confirm with C-peptide and GAD antibodies.
Which tests measure this biomarker
Fasting Insulin may be included in or ordered alongside these panels.
Any carbohydrate intake triggers large insulin surges within minutes. Strict fast is non-negotiable for a valid result.
More stable than insulin — not extracted by liver. Used to assess endogenous insulin production in patients on exogenous insulin.
The 10-year compensated phase: why detecting insulin early matters
Insulin resistance develops gradually over years. In the compensated phase, beta-cells increase insulin secretion to maintain normal glucose — fasting insulin is high while glucose is normal. This is the optimal intervention window. Over time, beta-cell exhaustion occurs — secretion can no longer compensate, fasting glucose rises, and overt T2DM develops. By the time diabetes is diagnosed by glucose criteria alone, 50–80% of beta-cell function has already been lost. Measuring fasting insulin reveals the dysfunction a decade before glucose testing becomes abnormal.
IR precedes T2DM by 10–15 years
Epidemiological studies show hyperinsulinaemia precedes impaired fasting glucose by 10–15 years. During this time, the standard diabetes screen (glucose, HbA1c) is negative. Fasting insulin testing reveals metabolic dysfunction in this preventive window — the rationale for measuring it in asymptomatic high-risk individuals.
Insulin's 4-minute half-life makes fasting mandatory
Insulin is cleared by the liver (50% first-pass) and kidney with a plasma half-life of just 4–6 minutes. Even a small carbohydrate intake triggers surges that wash out within 30 minutes. A strict 8–12h fast is non-negotiable for a meaningful fasting insulin measurement.
C-peptide is more accurate for beta-cell function
When proinsulin is cleaved, insulin and C-peptide are released in equimolar amounts. C-peptide is not extracted by the liver (no first-pass) and has a 20–30 minute half-life — making it a more stable measure of endogenous insulin production, particularly in patients who inject exogenous insulin.
Clinical use — when and why this is ordered
How clinicians use Fasting Insulin in practice — the real-world scenarios where it changes decisions.
Early metabolic risk detection
Elevated fasting insulin with normal glucose flags compensated insulin resistance — triggers lifestyle intervention years before T2DM develops.
PCOS investigation
Part of standard PCOS workup alongside LH:FSH, testosterone, and pelvic ultrasound — guides metformin initiation decision.
Hypoglycaemia investigation
Fasting insulin during hypoglycaemia (Whipple's triad) diagnoses insulinoma — paired with C-peptide and proinsulin measurements.
NAFLD risk stratification
High fasting insulin predicts NAFLD severity and progression to NASH — used alongside liver enzymes for comprehensive metabolic risk.